Results 231 to 240 of about 15,914 (251)
Some of the next articles are maybe not open access.
Recent developments in radioimmunotherapy
Clinical Oncology, 1994With the advent of monoclonal antibody techniques, there has been renewed interest in RIT as a treatment modality in patients with a variety of tumour types. There has been a considerable research effort to increase understanding of the scientific basis of such therapy at all levels.
K J, Harrington, A A, Epenetos
openaire +2 more sources
Radioimmunotherapy of Ovarian Cancer
Hybridoma, 1995Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration.
K N, Syrigos, A A, Epenetos
openaire +2 more sources
Microdosimetric concepts in radioimmunotherapy
Medical Physics, 1993In microdosimetry particular emphasis is placed on the stochastic fluctuation of dose in small target volumes such as individual cell nuclei or chromatin fiber, and their relevance to radiobiologic toxicity. Thus microdosimetry is intimately associated with models of radiation action.
J L, Humm +3 more
openaire +2 more sources
Review of clinical radioimmunotherapy
Expert Review of Anticancer Therapy, 2006Radioimmunotherapy involves a form of biologically targeted radiopharmaceutical treatment in which a radioactive isotope (typically a short-range, high-energy beta-emitter) is chemically bound to a target-specific monoclonal antibody or fragment. Thus, these radioimmunoconjugates combine the exquisite targeting specificity of the humoral immune system ...
Brad, Pohlman +2 more
openaire +2 more sources
Radioimmunotherapy in Brain Tumors
2012Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need
Grana, Chiara Maria, Paganelli, Giovanni
openaire +2 more sources
Radioimmunotherapy for Waldenstrom's macroglobulinemia
Seminars in Oncology, 2003Radioimmunotherapy targeting CD20 is a promising novel treatment for lymphoma. Prior trials have established the safe dose of Zevalin ((90)Y-ibritumomab tiuxetan; IDEC Pharmaceuticals) for patients with no more than 25% bone marrow (BM) involvement. Zevalin is expected to be an effective treatment for WM; however, the safe dose has not been defined.
openaire +2 more sources